A multicenter, randomized, double-blind, placebo-controlled phase III trial of tecemotide versus placebo in subject with completed concurrent chemo-radiotherapy for unresectable stage III non-small cell lung cancer (NSCLC)
|Effective start/end date||1/28/14 → 9/30/14|
- EMD Serono, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.